1. Home
  2. PBBK vs EQ Comparison

PBBK vs EQ Comparison

Compare PBBK & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PB Bankshares Inc.

PBBK

PB Bankshares Inc.

HOLD

Current Price

$19.81

Market Cap

53.5M

Sector

Finance

ML Signal

HOLD

EQ

Equillium Inc.

HOLD

Current Price

$1.13

Market Cap

57.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBBK
EQ
Founded
1919
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.5M
57.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PBBK
EQ
Price
$19.81
$1.13
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
10.8K
1.1M
Earning Date
02-25-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
53.39
N/A
EPS
0.98
N/A
Revenue
$13,918,000.00
$4,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$20.21
N/A
Revenue Growth
17.20
N/A
52 Week Low
$14.23
$0.27
52 Week High
$22.92
$2.35

Technical Indicators

Market Signals
Indicator
PBBK
EQ
Relative Strength Index (RSI) 43.68 44.46
Support Level $21.04 $1.43
Resistance Level $21.95 $1.61
Average True Range (ATR) 0.54 0.20
MACD -0.21 -0.02
Stochastic Oscillator 9.43 16.42

Price Performance

Historical Comparison
PBBK
EQ

About PBBK PB Bankshares Inc.

PB Bankshares Inc follows a community bank model and provides multiple services to individuals and small to midsize businesses. Its business consists of attracting retail and commercial deposits from the general public in its market area and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial and industrial loans, construction, home equity lines of credit and to a lesser extent, one- to four-family residential real estate loans and consumer loans.

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Share on Social Networks: